本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Inozyme Pharma

1.03
+0.05065.17%
盘后1.030.00000.00%17:44 EDT
成交量:49.58万
成交额:50.12万
市值:6,616.74万
市盈率:-0.63
高:1.04
开:0.9928
低:0.9758
收:0.9794
数据加载中...
2024/02/20

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/12

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/07

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/05

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/16

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/11/14

SEC问询函

Form CORRESP - Correspondence
2023/11/07

重要事件披露

Form 8-K - Current report
2023/11/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/09/26

重要事件披露

Form 8-K - Current report
2023/08/11

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/08/08

重要事件披露

Form 8-K - Current report
2023/08/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/08/08

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]